NGM's Series C Garners $50M for Ongoing Work in Diabetes
By Randy Osborne
Friday, July 19, 2013
With a handful of collaborations already under way, NGM Biopharmaceuticals Inc. raised $50 million in a Series C round to advance in-house efforts in cardiometabolic diseases, including diabetes and obesity.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.